Research programme: caspase inhibitors - Pfizer

Drug Profile

Research programme: caspase inhibitors - Pfizer

Latest Information Update: 27 Nov 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Idun Pharmaceuticals
  • Class
  • Mechanism of Action Caspase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Heart failure; Liver disorders; Myocardial infarction; Sepsis; Vascular disorders

Most Recent Events

  • 19 Apr 2005 Idun Pharmaceuticals has been acquired by Pfizer
  • 28 Oct 2003 This programme is still in active development
  • 15 Feb 2001 Preclinical development for Sepsis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top